Reporter brief
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
What happened
Trial registry update: TERMINATED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report efficacy outcomes or effect sizes, so no conclusions can be drawn about whether rapamycin actually improved vision or slowed disease progression
- The abstract does not report sample size or safety data, preventing assessment of whether adverse events were rare or common
- Without comparison to standard treatments or control groups, efficacy relative to existing age-related macular degeneration therapies cannot be determined from this abstract
Study design and sample
Rct; Human.
Patients with newly diagnosed, treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Design
- Rct
- Sample
- —
- Journal
- Santen Inc.
- Published
- Jan 10, 2013
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.